Clinical Research Directory

Inclusion Criteria: 1. Advanced solid tumors; 2. Measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1); 3. Eastern Cooperative Oncology Group (ECOG) performance status 0-1; 4. Adequate organ function; 5. Recover from all reversible AEs from previous anti-tumor treatment (i.e., Grade ≤ 1, according to National Cancer Institute-Common Terminology Criteria for Adverse Events \[NCI-CTCAE\] v5.0), excluding alopecia (any grade) and Grade ≤ 2 neuropathy peripheral. Exclusion Criteria: 1. Previous treatment with drugs targeting CLDN6 (including antibody-drug conjugates \[ADCs\]), or any drug containing topoisomerase I inhibitors (including ADCs); 2. Received prior chemotherapeutic, investigational, or other therapies for the treatment of cancer within 2 weeks with small molecule and within 4 weeks with biologic before the first dose of QLS5132; 3. Progressive or symptomatic brain metastases; 4. Serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection; 5. History of significant cardiac disease, or poorly controlled diabetes mellitus; 6. History of recurrent autoimmune diseases; 7. History of myelodysplastic syndrome (MDS) or Acute Myeloid Leukemia (AML); 8. History of a second primary malignancy; 9. If female, is pregnant or breastfeeding; 10. Be allergic to any component of QLS5132 or its excipients.